Osteoporosis, Postmenopausal
Conditions
Brief summary
This study was conducted among women who had previously received alendronate for 3 to 6 years during the Fracture Intervention Trial (FIT). Participants in the FLEX study were randomly assigned to receive alendronate (either 5 or 10 mg/day) or matching placebo during the next 5 years, in order to evaluate the effects of continuing or discontinuing alendronate treatment on bone mineral density and biochemical markers of bone turnover.
Interventions
DRUGMK0217, alendronate sodium / Duration of Treatment : 5 Years
DRUGComparator : placebo (unspecified) /Duration of Treatment : 5 Years
Sponsors
Organon and Co
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
60 Years to 86 Years
Healthy volunteers
No
Inclusion criteria
* To be eligible to participate in this study, women needed to have previously participated in the Fracture Intervention Trial (FIT) and to have been part of the group treated with alendronate in FIT * They needed to have received at least 3 years of treatment with alendronate in the FIT trial * In addition, their bone mineral density (BMD) at the hip needed to be better than it was at the start of FIT
Exclusion criteria
* Patients were excluded if they had conditions that contraindicated alendronate therapy and if they might have used other medications for the treatment of osteoporosis * Women were also excluded if BMD at the hip was below a certain level (T-score \<=-3.5); that is, if it were 3.5 standard deviations or more lower than the average for young adult women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total hip bone mineral density (BMD) | — |
Secondary
| Measure | Time frame |
|---|---|
| BMD of femoral neck, trochanter, and lumbar spine | — |
| Biochemical markers of bone turnover | — |
Outcome results
None listed